Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser

Isaac, Maram; Mireskandari, Kamiar; Tehrani, Nasrin

doi:10.1016/j.jaapos.2015.01.009

Cited by 52 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tip 1 PR gelişen olgularda hem zon I hem de zon II'de LF ve İVB tedavisinin etkinliğinin benzer olduğunu ancak İVB uygulanan olgularda takip sü-resinin daha uzun olduğunu bildirmişlerdir. 18 Kim ve ark. AAPR olgularında LF ile kombine İVB uygulamasının daha olumlu sonuçlar verdiğini, Menke ve ark.…”

Section: Discussionunclassified

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Özcan¹,

Con²,

Çelik³

2015

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

(sırasıyla, p<0,001, p<0,001, p<0,001, p<0,001). S So on nu uç ç: : İlimizde, genel PR görülme sık-lığının (%30) Türkiye ortalamasıyla benzer oranlarda görülmesine rağmen agresif seyirli arka PR (%3) ve şiddetli PR (%12,6) görülme sıklığının yüksek olduğu saptandı. Sunulan sağlık hizmetleri politikasının bir parçası olarak Şanlıurfa'da, PR hastalığını görmeyi tehdit edici seviyelere ulaşma-dan önce saptayabilmek için etkili ve uygun bir tarama programı oluşturulmalıdır.A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Prematüre retinopatisi; insidans; risk faktörleri A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To determine the current incidence and risk factors of retinopathy of prematurity (ROP) and to evaluate treatment choices of ROP. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Two hundred thirty four premature infants, whose the mean birth week was 30.6±2.3 weeks, who had been screened for ROP between May 2014 and June 2015 were enrolled this retrospective study. Infants with ROP were classified according to the gestational age and birth weight. Risk factors were analyzed in infants with ROP. Infants with in need of treatment have been treated, based on the severity of ROP, via either laser photocoagulation (LP) or intravitreal (IV) anti-VEGF injection or LP combined with IV anti-VEGF injection. R Re es su ul lt ts s: : Among the 234 infants, the mean gestational age (GA), mean birth weight (BW), mean follow-up period were 30.6±2.3 weeks, 1573±430 gram and 14.5±4 weeks respectively. Overall, the incidence at any stage of ROP was 30% and severe (Type 1) ROP was 12.6%. Seven of all patients diagnosed with Type 1 ROP had aggressive posterior ROP. The incidences of ROP in babies with gestational age (GA) ≥34 weeks or birth weight (BW) ≥2000 gram were 24% and 18% respectively. Among all risk factors contributed to development of ROP low GA, low BW, septicemia and respiratory distress syndrome were significantly associated with ROP (p<0.001, p<0.001, p<0.001, p<0.001 respectively). C Co on nc cl lu us si io on n: : Although the overall incidence of ROP (30 %) seems to be similar to the average of Turkey, incidence of aggressive post ROP (3%) and severe ROP (12.6 %) is much higher. As a part of general health polices, an effective and compatible screening programs for detecting ROP before reaching sight-threatening levels should be established for Şanlıurfa.

show abstract

Section: Discussionunclassified

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Özcan¹,

Con²,

Çelik³

2015

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

show abstract

“…One such study that included 13 infants found that there was no difference in visual acuity and refractive error in those preterm infants treated with intravitreal bevacizumab or laser for type 1 ROP in zone I or II. 77 This was also reported Review Retina in a study of 26 patients with stage 3 ROP treated with bevacizumab in whom involution of neovascularization, flattening of demarcation lines, and growth of differentiated vessels into capillary-devoid areas was noted. 78 In a larger study of 152 eyes with stage 3+ ROP in zone I or II, intravitreal pegaptanib combined with diode laser photocoagulation outperformed laser therapy and cryotherapy in reducing rates of recurrence of stage 3 disease.…”

Section: Anti-vascular Endothelial Growth Factormentioning

confidence: 59%

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Conrady¹,

Hartnett²

2017

US Ophthalmic Review

View full text Add to dashboard Cite

show abstract

“…A recent retrospective study by Isaac et al evaluated outcomes in infants with ROP in zone 1 or 2 posterior treated with laser therapy in comparison with intravitreal bevacizumab (IVB). The study reported a favorable outcome in 12/15 eyes in the IVB arm and 18/18 eyes in the laser arm, with a higher prevalence of myopia in the laser treatment arm [5].…”

Section: Antivascular Endothelial Growth Factor Versus Conventional Lmentioning

confidence: 80%

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

Patel

Ranjan

Wasserman

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser

Cited by 52 publications

References 24 publications

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

Incidence, Risk Factors and Treatment Outcomes of Retinopathy of Prematurity in the Southeastern Anatolian Region Province of Şanlıurfa in Turkey

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

Contact Info

Product

Resources

About